Skip to main content
Explore URMC

Michael W. Becker, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-4099

Fax: (585) 276-2596

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



Our adult blood and marrow transplantation/leukemia service uses a team-based approach to care for our patients. I work with a great lineup of physicians, advanced practice providers, nurses, patient care technicians and administrative assistants. Together, we achieve excellence for our patients.

I am a scientist by heart and a physician by training. During my residency, I cared for young patients with cancer, including acute leukemia, and their stories led to my area of focus. My research interests are bone marrow cancers and blood and marrow stem cell transplantation. My clinical practice is the direct application to this research. My goal is to be able to apply what I learn in the lab to the care of my patients in our clinic.

Conditions I Treat

- Blood and Marrow Stem Cell Transplantation
- Acute leukemia
- Chronic leukemia
- Myelodysplastic syndromes
- Bone Marrow Failure
- Myeloproliferative disorders
- Myeloma


The Becker lab studies malignant stem cell populations in myeloid neoplasms. By combining the power of cell sorting, qPCR based gene expression analysis and advanced normal and cancer stem cell models, we are now able to characterize the contribution of normal somatic tissue stem cells to the development of cancers, including Acute Myelogenous Leukemia and MDS. Our lab uses model systems and gene expression analysis to compare normal stem cells with their malignant counterparts with the goal of an improved understanding of the origins of cancer stem cells and to identify novel targets for therapy. We have employed a unique flow cytometry platform and analysis approach to differentiate normal and malignant stem cell and progenitor populations in patients undergoing treatment for AML and MDS. This platform allows us to assess the impact of therapy on malignant stem cell populations and their gene signatures in patients undergoing treatment of their disease. In addition, we are interested in the role of the microenvironment in supporting malignant stem cell populations.



  • Internal Medicine
  • Medical Oncology - American Board of Internal Medicine


MD | University of Cincinnati College of Medicine

Post-doctoral Training & Residency

07/01/1999 - 06/30/2002
Fellowship in Hematology/Oncology at University of Michigan Medical Center

07/01/1997 - 06/30/1999
Residency in Internal Medicine at University of Michigan Medical Center

06/24/1996 - 06/23/1997
Internship in Internal Medicine at University of Michigan Medical Center

VIEW ALL expand_more


Internal Medicine Research Award
Sponsor: University of Michigan
Location: Ann Arbor, Michigan

AOA (Junior class initiate)

Clinical Trials

MSKCC15-193 ~ A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Lead Researcher: Michael W Becker MD

The purpose of this study is to study the impact of stem cell dose on outcome after autologous transplant.

View Study Details

Phase 1b Study of PTC299 in Relapsed/Refractory Acute Leukemias

Lead Researcher: Michael W Becker MD

This is an open-label, non-randomized, Phase 1b study to evaluate the safety, pharmacokinetics (PK) profiles, and preliminary evidence of antitumor activity of PTC299 and the metabolite, O-desmethyl PTC299, in participants with relapsed/refractory acute myeloid leukemia (AML) who have exhausted standard available therapies known to provide clinical benefit. The study is designed as a series of cohort-based dose escalations. For each cohort, a minimum of 3 evaluable participants with PK and safety data will be assessed. Additional participants will be recruited if additional PK data are needed to assess mean exposure based on the observed variability.

View Study Details

A Program for Monitoring Minimal Residual Disease Following Treatment of Patients With Acute Myeloid Leukemia or High Grade Myelodysplastic Syndrome

Lead Researcher: Michael W Becker MD

This study is being performed to develop assays to determine the impact of the therapy patients receive for treatment of AML or MDS and to determine if these tests can identify those patients who are at a greater risk for having their disease relapse.

View Study Details


Journal Articles

Gasparetto M, Pei S, Minhajuddin M, Khan N, Pollyea DA, Myers JR, Ashton JM, Becker MW, Vasiliou V, Humphries KR, Jordan CT, Smith CA. "Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1." Haematologica.. 2017 Jun 0; 102(6):1054-1065. Epub 2017 Mar 09.

Hunter BD, Herr M, Meacham PJ, Barlaskar F, Evans AG, Burack WR, Liesveld JL, Becker MW, Milner LA, Constine LS, Dhakal S, Barr PM, Friedberg JW, Casulo C. "Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era." Clinical lymphoma, myeloma & leukemia.. 2017 Mar 0; 17(3):145-151. Epub 2016 Nov 23.

Reid RM, Baran A, Friedberg JW, Phillips GL, Liesveld JL, Becker MW, Wedow L, Barr PM, Milner LA. "Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective." Cancer medicine. 2016 Nov 0; 5(11):3059-3067. Epub 2016 Oct 03.